From: SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma
 |  | SYNJ2BP |  | |
---|---|---|---|---|
Clinicopathologic Variables | n | Low expression | High expression | P Value a |
Gender | Â | Â | Â | Â |
 Male | 84 | 32 | 52 |  |
 Female | 14 | 7 | 7 | 0.399 |
Age (years) | Â | Â | Â | Â |
 ≤ 60 | 71 | 28 | 43 |  |
 > 60 | 27 | 11 | 16 | 0.906 |
Hepatitis B status | Â | Â | Â | Â |
 Negative | 17 | 5 | 12 |  |
 Positive | 81 | 34 | 47 | 0.336 |
AFP(ng/ml) | Â | Â | Â | Â |
 <20 | 28 | 11 | 17 |  |
 ≥20 | 70 | 28 | 42 | 0.948 |
Liver cirrhosis | Â | Â | Â | Â |
 Presence | 81 | 5 | 12 |  |
 Absence | 17 | 34 | 47 | 0.336 |
Tumor size (cm) | Â | Â | Â | Â |
 ≤ 3 | 36 | 7 | 29 |  |
 >3 | 62 | 32 | 30 | 0.002 |
Tumor nodule number | Â | Â | Â | Â |
 Single | 47 | 7 | 40 |  |
 Multiple (≥2) | 51 | 32 | 19 | <0.001 |
Vascular invasion | Â | Â | Â | Â |
 Presence | 53 | 10 | 43 |  |
 Absence | 45 | 29 | 16 | <0.001 |
Child-Pugh classification | Â | Â | Â | Â |
 A | 76 | 31 | 45 |  |
 B | 22 | 8 | 14 | 0.709 |
TNM stage | Â | Â | Â | Â |
 I | 40 | 8 | 32 |  |
 II | 9 | 2 | 7 |  |
 III | 49 | 29 | 20 | <0.001 |
BCLC stage | Â | Â | Â | Â |
 0-A | 54 | 9 | 45 |  |
 B | 9 | 4 | 5 |  |
 C | 35 | 26 | 9 | 0.001 |
Edmonson-Steiner grade | Â | Â | Â | Â |
 I-II | 72 | 26 | 46 |  |
 III-IV | 26 | 13 | 13 | 0.215 |